Papers/PMID:22551330
Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review.
BJU international2012The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
Serenoa repens — decreases nocturnal voiding frequency (nocturia)
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1“Pooled analysis of nine short-term Permixon trials found a significant reduction in the frequency of nocturia with a WMD of −0.79 times/night [95% CI −1.28 to −0.29], although there was evidence of profound heterogeneity (I2 76%).”
Quoted verbatim from Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review.. - Study
- meta-analysis
- Population
- Nine short-term Permixon (Serenoa repens extract) trials vs placebo, men with LUTS consistent with BPH
Effect -0.79 mean difference, 95% CI -1.28 to -0.29
Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): an updated Cochrane systematic review.2012PMID:22551330Permalink